[
  {
    "ts": "2025-09-28T11:18:33+00:00",
    "headline": "A Fresh Look at Bristol Myers Squibb’s Valuation Following Its Patient Connect Expansion and Drug Discount Initiative",
    "summary": "If you have been keeping an eye on Bristol-Myers Squibb (BMY), you may have noticed recent buzz surrounding its newest move: an expansion of its direct-to-patient Patient Connect platform. The company just launched significant discounts for two of its prominent drugs, Sotyktu and Eliquis, for eligible US cash-paying patients. This is more than a small tweak to the business model and reflects Bristol-Myers Squibb’s broader efforts to adapt as the regulatory focus intensifies on drug pricing...",
    "url": "https://finance.yahoo.com/news/fresh-look-bristol-myers-squibb-111833366.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "8294e1d1-600c-3e1d-9581-e1d8a6a2268b",
      "content": {
        "id": "8294e1d1-600c-3e1d-9581-e1d8a6a2268b",
        "contentType": "STORY",
        "title": "A Fresh Look at Bristol Myers Squibb’s Valuation Following Its Patient Connect Expansion and Drug Discount Initiative",
        "description": "",
        "summary": "If you have been keeping an eye on Bristol-Myers Squibb (BMY), you may have noticed recent buzz surrounding its newest move: an expansion of its direct-to-patient Patient Connect platform. The company just launched significant discounts for two of its prominent drugs, Sotyktu and Eliquis, for eligible US cash-paying patients. This is more than a small tweak to the business model and reflects Bristol-Myers Squibb’s broader efforts to adapt as the regulatory focus intensifies on drug pricing...",
        "pubDate": "2025-09-28T11:18:33Z",
        "displayTime": "2025-09-28T11:18:33Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/isv7n73YBii.eJbbdO3fww--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MRv2ZxXw0SbLt6U2idf4TQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fresh-look-bristol-myers-squibb-111833366.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fresh-look-bristol-myers-squibb-111833366.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-28T01:07:15+00:00",
    "headline": "Why Bristol-Myers Squibb (BMY) Deserves a Spot in Passive Income Portfolios",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is included among the 12 Best Stocks to Buy Now for Passive Income. Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical company that many consider worth investing in and holding long-term. Its history dates back to the early 1800s, shaped by decades of drug innovation and strategic mergers. Today, the company […]",
    "url": "https://finance.yahoo.com/news/why-bristol-myers-squibb-bmy-010715829.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "fb2f2d32-ada2-3887-adfd-8a0658132e67",
      "content": {
        "id": "fb2f2d32-ada2-3887-adfd-8a0658132e67",
        "contentType": "STORY",
        "title": "Why Bristol-Myers Squibb (BMY) Deserves a Spot in Passive Income Portfolios",
        "description": "",
        "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is included among the 12 Best Stocks to Buy Now for Passive Income. Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical company that many consider worth investing in and holding long-term. Its history dates back to the early 1800s, shaped by decades of drug innovation and strategic mergers. Today, the company […]",
        "pubDate": "2025-09-28T01:07:15Z",
        "displayTime": "2025-09-28T01:07:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Why Bristol-Myers Squibb (BMY) Deserves a Spot in Passive Income Portfolios",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w_.mq2hxLlg_y2nUTx72ng--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/t6o8Kx8kFVS_oEolQVNGNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-bristol-myers-squibb-bmy-010715829.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-bristol-myers-squibb-bmy-010715829.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]